US Medical Affairs Rheumatology logo

Heart to Heart:
Experts Discuss Cardiovascular Risk in Rheumatoid Arthritis

RA disease control can improve CVD risk, contributing to overall patient health and wellness1–4

Love icon

Podcast

The experts

Christina Charles-Schoeman, MD

Christina Charles-Schoeman, MD

Professor of Medicine and Chief of the Division of Rheumatology; UCLA

Roy M. Fleischmann, MD

Roy M. Fleischmann, MD

Clinical Professor of Medicine; University of Texas Southwestern

Key information

Heart icon

Risk

Patients with RA have a 50% higher risk of CVD death, compared to the general population5*

Goal icon

Disease control

Achieving remission can reduce the risk of CVD6†

decorative

How often do you talk to your patients with RA about CVD risk?

What you can do today for your patients with RA8

Checkmark icon

Start DMARDs as soon as RA is diagnosed

Checkmark icon

Educate patients with RA on CVD risk

Checkmark icon

Assess CVD risk at least every 5 years

Including lipid level assessment

Checkmark icon

Adapt CVD risk calculators for RA;

Multiply by 1.5x for RA

Checkmark icon

Co-manage with a team

including cardiologists and PCPs9

Sustained remission or LDA is the goal in every patient 8, 10, 11

decorative

How likely are you to regularly assess CVD risk in your patients with RA?

Very unlikely Very likely

Resource

PDF icon

Find out more about CVD risk in patients with RA

We value your feedback

CV, cardiovascular; CVD, cardiovascular disease; DMARD; disease-modifying antirheumatic drug; LDA, low disease activity; PCP, primary care provider; RA, rheumatoid arthritis.

*From a meta-analysis of 24 case-controlled and cohort studies ranging from 1970–2005 with a total of 111,758 patients.

Records analysis of 525 patients with RA and 524 age- and sex- matched controls; patients in Minnesota were diagnosed 1988–2007 and followed through 2012.

1. Mehta B, et al. RMD Open. 2019;5(1):e000935;
2. van Diepen S, et al. Circulation. 2008;118(19):1946–1952;
3. Elandt K, Aletaha D. Arthritis Res Ther. 2011;13(3);223;
4. Scott IC, et al. RMD Open. 2016;2(2):e000270;
5. Aviña-Zubieta JA, et al. Arthritis Rheum. 2008;59(12):1690–1697;
6. Myasoedova E, et al. Ann Rheum Dis. 2016;75(3):560–565; 
7. Crowson CS, et al. Ann Rheum Dis. 2018;77(1):48–54;
8. Agca R, et al. Ann Rheum Dis. 2017;76(1):17–28;
9. Guerra JD, et al. Clin Rheumatol. 2022;41(12):3715–3724;
10. Smolen JS, et al. Ann Rheum Dis. 2023;82:3–18.
11. Fraenkel L, et al. Arthritis Care Res (Hoboken). 2021;73(7): 924–939.

The US Medical Affairs department of AbbVie Inc. is the copyright owner of this presentation and has paid RheumNow to host this content. AbbVie is solely responsible for all written content within this presentation.
© 2023 AbbVie Inc. All rights reserved. ABBV-US-01227-MC v1.0 Approved April 2023